F-1: Bionomics Files for Resale of ADSs Following Private Placement

Bionomics Limited has filed a registration statement for the resale of American Depositary Shares (ADSs) by a selling shareholder after a recent private placement.

Summary

• Bionomics Limited has filed a registration statement on Form F-1 with the SEC for the offer and resale of up to 20,228,963 American Depositary Shares (ADSs) by a selling shareholder.
• These ADSs represent 3,641,213,340 ordinary shares, including those issuable upon exercise of warrants.
• The ADSs were initially issued pursuant to a Securities Purchase Agreement dated May 31, 2024, between Bionomics and the selling shareholder.
• Bionomics will not receive any proceeds from the sale of ADSs by the selling shareholder, except for up to US$12.7 million if the warrants are exercised.
• The company intends to use the net proceeds from the warrant exercises to fund the advancement of BNC210's registrational programs, business development activities, working capital, and general corporate purposes.
• Bionomics is a clinical-stage biopharmaceutical company focused on developing novel, allosteric ion channel modulators for central nervous system (CNS) disorders.
• The company's lead product candidate, BNC210, is being developed for the chronic treatment of Post-Traumatic Stress Disorder (PTSD) and the acute treatment of Social Anxiety Disorder (SAD).
• Bionomics will cease to qualify as a foreign private issuer on July 1, 2024, and will begin reporting as a domestic issuer under the Securities Exchange Act of 1934 from that date.

Sentiment

Score: 6

Explanation: The document is primarily a regulatory filing related to a secondary offering, so the sentiment is neutral. The company has potential upside from warrant exercises, but also faces risks associated with drug development and regulatory hurdles.

Positives

• The potential exercise of warrants could provide Bionomics with up to US$12.7 million in additional funding.
• The funds are earmarked for advancing BNC210, a key asset in Bionomics' pipeline, through registrational programs for PTSD and SAD.
• The company has reached an agreement with the FDA on the plan to conduct two single dose randomized, placebo-controlled studies.
• The company has initiated dosing in the Phase 3 study in SAD in the third quarter of 2024.

Negatives

• Bionomics will not receive any proceeds from the resale of ADSs by the selling shareholder unless the warrants are exercised.
• The company is dependent on MSD to provide updates related to clinical trial results, serious adverse events and ongoing communications with FDA or other regulatory agencies related to these programs, which MSD may provide or withhold in its sole discretion.
• The company will cease to qualify as a foreign private issuer on July 1, 2024, and will begin reporting as a domestic issuer under the Securities Exchange Act of 1934 from that date, which could result in additional costs.

Risks

• Sales of a substantial amount of the ADSs in the public markets, as a result of the exercise of the Warrants or otherwise, could cause the market price of the ADSs to decline.
• The company faces competition from entities that have developed or may develop product candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours.
• The company is a clinical-stage biopharmaceutical company with no approved products.
• The company has incurred significant operating losses since its inception and expect to incur significant losses for the foreseeable future.
• The company has never generated any revenue from product sales and may never generate any revenue or become profitable or, if it achieves profitability, it may not be able to sustain it.
• The company will require substantial additional financing to achieve its goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
• Preclinical and clinical drug development is a lengthy and expensive process, with an uncertain outcome.
• The company's preclinical and clinical programs may experience delays or may never advance, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.
• If the company experiences delays or difficulties in the initiation, enrollment and/or retention of patients in clinical trials, our regulatory submissions or receipt of necessary regulatory approvals could be delayed or prevented.
• The trading price of our ordinary shares has been volatile, and that of our ADSs may be volatile, and you may not be able to resell the ADSs at or above the price you paid.
• An active trading market for the ADSs may not be maintained or be liquid enough for you to sell your ADSs quickly or at market price.
• Your right as a holder of ADSs to participate in any future preferential subscription rights offering or to elect to receive dividends in ordinary shares may be limited, which may cause dilution to your holdings.
• The company's current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
• The company may have difficulties in attracting and retaining key personnel, and if we fail to do so our business may suffer.
• The company depends on collaboration partners to develop and commercialize our collaboration product candidates, including Merck and Carina Biotech. If our collaboration partners fail to perform as expected, fail to advance our collaboration product candidates or are unable to obtain the required regulatory approvals for our collaboration product candidates, the potential for us to generate future revenue from such product candidates would be significantly reduced and our business would be significantly harmed.
• The company currently relies, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.
• The company may not be able to protect our intellectual property rights throughout the world.

Future Outlook

Bionomics plans to initiate a Phase 3 study in PTSD in the fourth quarter of 2024, contingent upon successful capital raise and FDA interactions. Start-up activities for a planned Phase 3 trial of BNC210 in SAD are underway, with dosing initiated in the third quarter of 2024.

Industry Context

Bionomics is operating in the biopharmaceutical industry, specifically targeting central nervous system (CNS) disorders. The company's focus on ion channel modulators aligns with a growing interest in novel therapeutic approaches for anxiety, PTSD, and cognitive dysfunction. The partnership with Merck & Co. highlights the industry's trend of collaboration between smaller biotech firms and larger pharmaceutical companies to leverage expertise and resources in drug development.

Comparison to Industry Standards

• Bionomics' approach to developing allosteric modulators for ion channels is comparable to that of other companies in the CNS space, such as Sage Therapeutics (focusing on GABA-A receptor modulation) and Karuna Therapeutics (targeting muscarinic receptors).
• The company's partnership with Merck for 7 receptor PAMs mirrors similar collaborations in the Alzheimer's disease field, where companies like AC Immune have partnered with Roche to develop therapeutics targeting amyloid and tau proteins.
• The Phase 2b ATTUNE study results for BNC210 in PTSD are being compared to outcomes from trials of other PTSD treatments, such as those involving SSRIs and SNRIs, to assess its potential advantages in efficacy and side effect profile.
• The company's decision to advance BNC210 into Phase 3 trials for SAD following an End-of-Phase 2 meeting with the FDA is a common pathway for biopharmaceutical companies seeking regulatory approval for their drug candidates.

Related Party Transactions

• David Wilson, a director of Bionomics, is the Chief Executive Officer of WG Partners.
• From December 1, 2023 through June 14, 2024, Bionomics paid WG Partners US$89,112 in monthly fees and a commission of US$100,000 in connection with the Private Placement.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The success of BNC210 development will impact patients suffering from PTSD and SAD.
• Employees' job security and opportunities are tied to the company's financial performance and drug development progress.
• The company's financial health affects its ability to meet obligations to suppliers and creditors.

Next Steps

• The selling shareholder may offer and sell the ADSs from time to time.
• Bionomics plans to initiate a Phase 3 study in PTSD in the fourth quarter of 2024, contingent upon successful capital raise and FDA interactions.
• Start-up activities for a planned Phase 3 trial of BNC210 in SAD are underway, with dosing initiated in the third quarter of 2024.

Key Dates

Keywords

ADS, Bionomics, Registration Statement, Private Placement, BNC210, Warrants, PTSD, SAD, Resale, Shares